Portal de Periódicos da CAPES

Defining Surrogate Serologic Tests with Respect to Predicting Protective Vaccine Efficacy: Poliovirus Vaccination

1995; Wiley; Volume: 754; Issue: 1 Linguagem: Inglês

10.1111/j.1749-6632.1995.tb44462.x

1749-6632

Roland W. Sutter, Mark A. Pallansch, Leigh A. Sawyer, Stephen L. Cochi, Stephen C. Hadler,

Animal Virus Infections Studies

Annals of the New York Academy of SciencesVolume 754, Issue 1 p. 289-299 Defining Surrogate Serologic Tests with Respect to Predicting Protective Vaccine Efficacy: Poliovirus Vaccination ROLAND W. SUTTER, Corresponding Author ROLAND W. SUTTER National Immunization Program, Centers for Disease Control and Prevention Atlanta, Georgia 30333Address for correspondence: Roland W. Sutter, M.D., M.P.H. & T. M., National Immunization Program (E61), Centers for Disease Control and Prevention, Atlanta, Georgia 30333.Search for more papers by this authorMARK A. PALLANSCH, MARK A. PALLANSCH Division of Viral and Rickettsial Diseases Centers for Disease Control and Prevention Atlanta, Georgia 30333Search for more papers by this authorLEIGH A. SAWYER, LEIGH A. SAWYER Division of Viral Products Center for Biologics Evaluation and Research United States Food and Drug Administration Bethesda, Maryland 20852Search for more papers by this authorSTEPHEN L. COCHI, STEPHEN L. COCHI National Immunization Program, Centers for Disease Control and Prevention Atlanta, Georgia 30333Search for more papers by this authorSTEPHEN C. HADLER, STEPHEN C. HADLER National Immunization Program, Centers for Disease Control and Prevention Atlanta, Georgia 30333Search for more papers by this author ROLAND W. SUTTER, Corresponding Author ROLAND W. SUTTER National Immunization Program, Centers for Disease Control and Prevention Atlanta, Georgia 30333Address for correspondence: Roland W. Sutter, M.D., M.P.H. & T. M., National Immunization Program (E61), Centers for Disease Control and Prevention, Atlanta, Georgia 30333.Search for more papers by this authorMARK A. PALLANSCH, MARK A. PALLANSCH Division of Viral and Rickettsial Diseases Centers for Disease Control and Prevention Atlanta, Georgia 30333Search for more papers by this authorLEIGH A. SAWYER, LEIGH A. SAWYER Division of Viral Products Center for Biologics Evaluation and Research United States Food and Drug Administration Bethesda, Maryland 20852Search for more papers by this authorSTEPHEN L. COCHI, STEPHEN L. COCHI National Immunization Program, Centers for Disease Control and Prevention Atlanta, Georgia 30333Search for more papers by this authorSTEPHEN C. HADLER, STEPHEN C. HADLER National Immunization Program, Centers for Disease Control and Prevention Atlanta, Georgia 30333Search for more papers by this author First published: May 1995 https://doi.org/10.1111/j.1749-6632.1995.tb44462.xCitations: 45AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Strebel, P. M., R. W. Sutter, S. L. Cochi et al. 1992. Epidemiology of poliomyelitis in the United States: One decade after the last reported case of indigenous wild virus-associated disease. Clin. Infect. Dis. 14: 568–579. 2 Centers for Disease Control and Prevention 1992. Summary of notifiable diseases, United States, 1991. Morb. Mortal. Wkly. Rep. 40(No. 53): 1–63. 3 World Health Organization (Expanded Program on Immunization). 1989. Poliomyelitis in 1986, 1987, and 1988 (Part I). Wkly. Epidemiol. Rec. 37: 273–279. 4 World Health Organization (Expanded Program on Immunization). 1989. Poliomyelitis in 1986, 1987, and 1988 (Part II). Wkly. Epidemiol. Rec. 37: 281–285. 5 Foote, F. M., G. Kraus, M. D. Andrews & J. C. Hart 1973. Polio outbreak in a private school. Conn. Med. 37: 643–644. 6 Schonberger, L. B., J. Kaplan, R. Kim-Farley, M. Moore, D. L. Eddins & M. Hatch 1984. Control of paralytic poliomyelitis in the United States. Rev. Infect. Dis. 6(Suppl.): S424–S426. 7 Evaluation OF the 1954 Field Trial OF Poliomyelitis Vaccine. Summary Report. 1955. University of Michigan. Ann Arbor, MI. 8 Grabenstein, J. D. 1993. ImmunoFacts: Vaccines & Immunologic Drugs. Facts & Comparisons. st. Louis , MO . 562. 9 Centers for Disease Control and Prevention: Poliomyelitis 1987. Poliomyelitis prevention: Enhanced-potency inactivated vaccine-Supplementary statement. Recommendations of the Advisory Committee on Immunization Practices. Morbid. Mortal. Wkly. Rep. 36: 795–798. 10 Horstmann, D. M. 1961. Factors affecting optimum dosage levels of live poliovirus vaccine. In Papers and Discussions Presented at the 5th International Poliomyelitis Conference in Copenhagen, Denmark: 304–310. J. B. Lippincott, Philadelphia PA . 11 Robertson, H. E., M. S. Acker, H. O. Dillenberg et al. 1962. Community-wide use of a “balanced” trivalent oral poliovirus vaccine (Sabin). A report of the 1961 trial at Prince Albert, Saskatchewan. Can. J. Public Health 53: 179–191. 12 Centers for Disease Control and Prevention 1992. Update: Eradication of paralytic poliomyelitis in the Americas. Morbid. Mortal. Wkly. Rep. 41: 681–683. 13 Dequadros, C. A., J. K. Andrus, J. M. Olive et al., 1991. Eradication of poliomyelitis: Progress in the Americas. Pediatr. Infect. Dis. J. 10: 222–229. 14 World Health Organization 1988. Global eradication of poliomyelitis by the year 2000. Wkly. Epidemiol. Rec. 63: 161–162. 15 Nightingale, E. O. 1977. Recommendations for a national policy on poliomyelitis vaccination. N. Engl. J. Med. 297: 249–253. 16 Institute of Medicine. 1988. An evaluation of poliomyelitis vaccine policy options. National Academy of Sciences (Publication No. IOM-88–04). Washington , DC . 17 Domok, I., M. S. Balayan, O. A. Fayinka et al. 1974. Factors affecting the immunogenicity of live poliovirus vaccine in warm climates: Efficacy of type 1 Sabin vaccine administered together with antihuman gamma globulin horse serum to breast-fed and artificially fed infants in Uganda. Bull. WHO 51: 333–347. 18 Patriarca, P. A., P. F. Wright & T. J. John 1991. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries. Rev. Infect. Dis. 13: 926–939. 19 Mcbean, A. M., M. L. Thoms, P. Albrecht, J. C. Cuthie, R. Bernier and the field Staff and Coordinating Committee 1988. Serologic response to oral polio vaccine and enhanced-potency inactivated polio vaccines. Am. J. Epidemiol. 128: 615–628. 20 Sutter, R. W. & P. A. Patriarca 1993. Inactivated and live, attenuated poliovirus vaccines: Mucosal immunity. In Measles and Poliomyelitis-Vaccines and Immunization. Kurstak Edouard, Ed.: 279–294. Springer. New York , NY . 21 Albrecht, P., J. C. Enterline, E. J. Boone & M. J. Klutch 1983. Poliovirus and polio antibody assay in HEp-2 and Vero cell cultures. J. Biol. Stand. 11: 91–97. 22 Pettit, C., L. L. Minnich, Z. M. Shehab & G. C. Ray 1987. Comparison between in direct immunofluorescence and microneutralization for detection of antibodies to polio-viruses. J. Clin. Microbiol. 25: 1325–1326. 23 Hodes, H. L., R. Berger, E. Ainbender, H. D. Zepp & M. M. Hevizy 1996. Study of viral antibodies by the paper-radioactive virus method. Pediatrics 37: 7–18. 24 Hagenaars, A. M., R. W. Van Delft, J. Nagel, G. Van Steenis & A. L. Van Wezel 1993. A modified ELISA technique for the titration of antibodies to polio virus as an alternative to a virus neutralization test.. J. Virol. Methods 6: 233–239. 25 Esposito, J. J. 1976. Detection of poliovirus antigens and antibodies: Microindirect haemagglutination and haemagglutination inhibition tests for poliovirus types I, II, and III. Microbios 16: 29–36. 26 Expanded Programme on Immunization 1991. Report of a WHO Consultation on Polio Neutralization Antibody Assays. Nashville, TN, USA, 5–6 December 1991. World Health Organization. Geneva . (WHO/EPI/RD/91.3). 27 Lyng, J. & M. Weis Bentson 1963. International standards for antipoliovirus sera types 1, 2, and 3. Bull. WHO 29: 711–720. 28 Boone, E. J. & P. Albrecht 1983. Conventional and enhanced plaque neutralization assay for polio antibody. J. Virol. Methods 6: 193–202. 29 Inouye, S., S. Matsuno & H. Yamaguchi 1984. Efficient coating of the solid phase with rotavirus antigens for enzyme-linked immunosorbent assay of immunoglobulin A antibody in feces. J. Clin. Microbiol. 19: 259–263. 30 Mckay, H. W., Jr., A. R. Fodor & U. P. Kokko 1963. Viremia following the administration of live poliovirus vaccines. Am. J. Public Health 53: 274–285. 31 Horstmann, D. M., R. W. Mccollum & A. D. Mascola 1954. Viremia in human poliomyelitis. J. Exp. Med. 99: 355–369. 32 Brown, G. C., A. S. Rabson & J. H. Schieble 1955. The effect of gamma globulin on subclinical infection in familial associates of poliomyelitis cases: II. Serological studies and virus isolations from pharyngeal secretions. J. Immunol. 74: 71–80. 33 Nathanson, N. & D. Bodian 1962. Experimental poliomyelitis following intramuscular virus injection. III. The effect of passive antibody on paralysis and viremia. Bull. Johns Hopkins Hosp. 111: 198–220. 34 Hammon, W. M., L. L. Cornell, P. F. Wehrle & J. Stokes 1953. Evaluation of Red Cross globulin as prophylactic agent for poliomyelitis. 4. Final report of results based on clinical diagnoses. JAMA 151: 1272–1285. 35 National Advisory Committee for the Evaluation of Gamma Globulin in the Prophylaxis of Poliomyelitis 1954. Gamma Globulin in the Prophylaxis Poliomyelitis. Public Health Monograph No. 20. Public Health Service Publication No. 358. U.S. Department of Health, Education and Welfare. Washington , DC . 36 Stevens, K. M. 1959. Estimate of molecular equivalents of antibody required for prophylaxis and therapy of poliomyelitis. J. Hyg. 57: 198–200. 37 Youngner, J. S. 1953. Poliovirus antibody in different lots of human sera gamma globulin.. Proc. Soc. Exp. Biol. Med. 84: 697–699. 38 Bahlke, A. M. & J. E. Perkins 1945. Treatment of pre-paralytic poliomyelitis with gammaglobulin. JAMA 129: 1146–1150. 39 Sutter, R. W. & D. R. Prevots 1994. Vaccine-associated paralytic poliomyelitis among immunologically abnormal persons. Int. Med. 11: 426, 429–430, 435–438. 40 Mermel, L., D. Sanchez de Mora, R. W. Sutter & M. A. Pallansch 1993. Vaccineassociated paralytic poliomyelitis. N. Engl. J. Med. 329: 810–811. 41 Sutter, R. W, P. A. Patriarca, S. Brogan et al., 1991. An outbreak of paralytic poliomyelitis in Oman: Evidence for widespread transmission among fully vaccinated children. Lancet 338: 715–720. 42 Paul, J. R, J. T. Riordan & J. L. Melnick 1951. Antibodies to three different antigenic types of polioviruses in Sera from Northern Alaskan Eskimos. Am. J. Hyg. 54: 275–285. 43 Nissen, K. I. 1947. Poliomyelitis on St. Helena, 1945–46. Proc. R. Soc. Med. 40: 923–927. 44 Otten, M. W., M. S. Deming, K. O. Jaiteh et al., 1992. Epidemic poliomyelitis in The Gambia following control of poliomyelitis as an endemic disease. I. Descriptive findings. Am. J. Epidemiol. 135: 381–392. 45 Deming, M. S., K. O. Jaiteh, M. W. Otten et al. 1992. Epidemic poliomyelitis in The Gambia following control of poliomyelitis as an endemic disease. II. Clinical efficacy of trivalent polio vaccine. Am. J. Epidemiol. 135: 393–408. 46 Oker-Bloom, N., K. Penttinen & P. Weckström 1984. Inactivated poliovirus vaccine in Finland. Rev. Infect. Dis. 6:(Suppl.): S461–S462. 47 Shimojo, H. 1984. Poliomyelitis control in Japan. Rev. Infect. Dis. 6:(Suppl.): S427–S430. 48 Strebel, P. M., R. W. Sutter, S. L. Cochi, O. M. Kew & M. A. Pallansch 1991. Risk of vaccine-associated paralytic poliomyelitis (VAPP) and potential impact of a sequential eIPV/OPV vaccination schedule. In Program and Abstracts. The 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology. Washington , DC . (Abstr. No. 1369: 327). 49 Who Collaborative Study Group on Oral Poliovirus Vaccine [P. A. Patriarca] 1992. A randomized trial of alternative formulations of oral poliovirus vaccine (OPV) in Brazil and The Gambia. In Program and Abstracts. The 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology. Washington , DC . (Abstr. No. 916: 263). 50 Patriarca, P. A., F. Laender, G. Palmeira et al. 1988. Randomized trial of alternative formulations of oral poliovaccine in Brazil. Lancet i: 429–433. 51 Moriniere, B., F. Van Loon, B. Frank et al., 1993. Immunogenicity of a supplemental dose of oral versus inactivated poliovirus vaccine. Lancet 341: 1545–1550. 52 Modlin, J. F., N. A. Halsey, M. L. Thoms, C. K. Meschievitz & P. A. Patriarca 1993. Serum neutralizing antibody response to three experimental sequential IPV-OPV immunization schedules. In Program and Abstracts. The 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology. Washington , DC . (Abstr. No. 1239: 346). 53 Faden, H. S., J. F. Modlin, M. L. Thoms et al., 1990. Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: Systemic and local immune responses. J. Infect. Dis. 162: 1291–1297. 54 Onorato, I. M., J. F. Modlin, A. M. Mcbean et al., 1991. Mucosal immunity induced by enhanced-potency inactivated and oral polio vaccines. J. Infect. Dis. 163: 1–6. 55 Faden, H.L., Duffy, M. & C. Shuff 1993. Long-term immunity to poliovirus in children immunized with live attenuated and enhanced-potency inactivated poliovirus vaccines. J. Infect. Dis. 168: 452–454. 56 Davisson, E. O., H. M. Powell, J. O. Macfarlane, R. Hodgson, R. L. Stone & C. G. Culbertson 1956. The preservation of poliomyelitis vaccine with stabilized merthiolate. J. Lab. Clin. Med. 47: 8–19. 57 Sawyer, L., J. Mcinnis & P. Albrecht 1992. Deleterious effect on thimerosal on inactivated poliovirus vaccine (IPV). In Program and Abstracts. The 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology. Washington , DC . (Abstr. No. 1400: 344). 58 Sawyer, L. A., J. Mcinnis, A. Patel, A. D. Horne & P. Albrecht Deleterious effect of thimerosal on the potency of inactivated poliovirus vaccine. Vaccine. In press. 59 Fritzell, B. 1992. Combination DTP/elPV development status. Polio Immunization: Strategy Update. Symposium (abstr.) held during the Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, California, October 10, 1992. 60 Dagan, R., I. Butossensky, C. Etheveneux & B. Fritzell 1993. Haemophilus influenzae type b (Hib)-tetanus toxoid conjugate (PRPT) mixed with diphtheria-pertussistetanus-inactivated polio (DTP-IPV) in infants. In Program and Abstracts. The 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology. Washington, DC. (Abstr. No. 301: 174). Citing Literature Volume754, Issue1Combined Vaccines and Simultaneous Administration: Current Issues and PerspectivesMay 1995Pages 289-299 ReferencesRelatedInformation